- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Sarah Cannon Research Institute | Strategic Alliance Partners
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. In 2022, SCRI joined with former US Oncology Research to expand clinical trial access across the country. It has conducted more than 750 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. SCRI’s research network brings together more than 1,300 physicians who are actively enrolling patients into clinical trials at more than 250 locations in 24 states across the U.S. Learn more about our research offerings.
Latest from Sarah Cannon Research Institute
Dr. Yardley Shares Insight on the Impact of Biosimilars
August 29, 2018
Video
Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, shares insight on the potential impact of biosimilars in breast cancer.
Falchook Sheds Light on Rare Oncogenic Drivers in NSCLC
August 28, 2018
Article
Patients with mutations in NTRK, RET, MET, HER2, and KRAS G12C have limited therapeutic options, but potentially promising agents are on the horizon.
Dr. Yardley Discusses Data With Talazoparib in Breast Cancer
August 27, 2018
Video
Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses data with talazoparib in breast cancer.
Dr. Van Veldhuizen Reflects on the CARMENA Trial in RCC
August 20, 2018
Video
Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses the impact of the CARMENA trial results in renal cell carcinoma.
Emerging Approaches Offer Hope in Heavily Pretreated Myeloma
August 07, 2018
Article
Suman Kambhampati, MD, discusses some of the latest developments in the treatment of patients with relapsed/refractory multiple myeloma.
Yardley Recaps Breast Cancer Data From ASCO 2018
August 02, 2018
Article
Denise A. Yardley, MD, weighs in on the recent data reported in breast cancer.
Dr. Berdeja on FDA Approval of Frontline Daratumumab Plus VMP in Multiple Myeloma
May 08, 2018
Video
Jesus G. Berdeja, MD, director of Myeloma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of frontline daratumumab (Darzalex) in combination with bortezomib (Velcade), melphalan, and prednisone (VMP) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).
Dr. Flinn on FDA Approval of Tisagenlecleucel in DLBCL
May 02, 2018
Video
Ian W. Flinn, MD, PhD, director of Lymphoma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of the chimeric antigen receptor T-cell therapy tisagenlecleucel (Kymriah) for use in adult patients with relapsed/refractory large B-cell lymphoma—including diffuse large B-cell lymphoma.
Dr. Bachier Discusses Toxicities With Stem Cell Transplant
March 30, 2018
Video
Carlos R. Bachier, MD, director, blood and marrow transplant research, Sarah Cannon Research Institute, discusses toxicities associated with stem cell transplant.
Dr. Donnellan Discusses Trials in Hematologic Malignancies
March 28, 2018
Video
William B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, discusses ongoing trials in hematologic malignancies.
Dr. Donnellan on Combinations Under Investigation in Acute Leukemia
March 21, 2018
Video
William B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, discusses combinations under investigation in acute leukemia.
Dr. Flinn on FDA Approval of Frontline Brentuximab Vedotin With AVD in Hodgkin Lymphoma
March 20, 2018
Video
Ian W. Flinn, MD, PhD, director of Lymphoma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of brentuximab vedotin (Adcetris) combined with Adriamycin, vinblastine, and dacarbazine (AVD) as a frontline treatment for patients with advanced classical Hodgkin lymphoma.
Dr. Bachier Discusses CAR T-Cell Therapy and Stem Cell Transplant
March 13, 2018
Video
Carlos R. Bachier, MD, program director of Sarah Cannon Center for Blood Cancer, Sarah Cannon Research Institute, discusses the relationship between chimeric antigen receptor (CAR) T-cell therapy and stem cell transplant.
Dr. Spigel on the Rationale Behind the PACIFIC Trial
March 08, 2018
Video
David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the rationale behind the design of PACIFIC, a trial that investigated the use of durvalumab (Imfinzi) in patients with locally advanced, unresectable stage III lung cancer.
Flinn Sheds Light on Advances in MCL and Other Lymphomas
March 06, 2018
Article
Ian W. Flinn, MD, PhD, discusses the impact of CAR T-cell therapy on the field of lymphoma and highlighted emerging options for the treatment of patients with MCL.
Dr. Kambhampati Discusses the Current Landscape of MDS
March 05, 2018
Video
Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses the current landscape of myelodysplastic syndromes (MDS).
Dr. Donnellan Reflects on FDA Approvals in Acute Leukemia
March 02, 2018
Video
William B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, reflects on some of the most pivotal FDA approvals in acute leukemia in the past year.
Spigel Reflects on Recent Immunotherapy Success in Stage III NSCLC
March 02, 2018
Article
David R. Spigel, MD, discusses the status of immunotherapy in locally advanced NSCLC and highlights recent milestones.
Myeloma Expert Provides Insight on Practice-Changing Data
March 02, 2018
Article
Jesus Berdeja, MD, provides an update on practice-changing data for the treatment of patients with multiple myeloma.
Efforts Continue to Enhance Stem Cell Transplants
March 01, 2018
Article
Carlos R. Bachier, MD, discusses the evolution of stem cell transplantation as a treatment for patients with hematologic malignancies.